Recap: 2025 Revolutionizing Atopic Dermatitis Conference

To stay informed with all conference insights, subscribe to receive our eNewsletters.

Previewing the 2025 Revolutionizing Atopic Dermatitis Conference

Catch up on what to expect at this year's RAD conference in Nashville, Tennessee.

Road to RAD: Dermatology Times Board Member Presenters

Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025

Arcutis Biotherapeutics showcases promising long-term results of Zoryve for atopic dermatitis in young children at RAD 2025, emphasizing safety and efficacy.

Road to RAD: What to Expect

Co-chairs Jonathan Silverberg, MD, PhD, MPH, and Raj Chovatiya, MD, PhD, MSCI, gave insight into what attendees can look forward to at this year's meeting.

SCALE UP Demonstrates AD Symptom Relief Across All Skin Types With Upadacitinib

A poster at RAD 2025 detailed the patient-reported outcomes across skin types and racial groups.

Spotlighting Biologic Advancements and Novel Pathways in Atopic Dermatitis

At RAD 2025, Jonathan Silverberg, MD, PhD, MPH, provided an in-depth look at the clinical integration of newly approved biologics nemolizumab and lebrikizumab in AD.

INTEGUMENT-INFANT Phase 2 Trial Will Assess Roflumilast in Pediatric Patients with AD

Discover groundbreaking insights from the RAD 2025 conference on roflumilast's potential to transform treatment for infant atopic dermatitis.

The Psychosocial Toll of Atopic Dermatitis Across All Ages

At RAD 2025, Mona Shahriari, MD, emphasized the cumulative life course impairment of AD in pediatric and adult patients, highlighting its impact on sleep, mental health, family well-being, and quality of life.

Day 1 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Catch up on coverage from the first day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

Dupilumab Significantly Enhances Quality of Life and Reduces Cumulative Impairment in Patients with Moderate to Severe Atopic Dermatitis

Data presented at the 2025 RAD Conference shows dupilumab improves daily functioning, mental health, and social aspects in patients with atopic dermatitis.

Addressing Overlapping Pathophysiology and Patient Burden in Atopic Dermatitis and Alopecia Areata

At RAD 2025, Tiffany Mayo, MD, emphasized the need for clinicians to recognize shared inflammatory mechanisms between AD and AA.

Q&A: Reframing JAK Inhibitor Safety and Flexibility in AD With Leon Kircik, MD

At the 2025 Revolutionizing Atopic Dermatitis Conference, Leon Kircik, MD, highlighted the safety of JAK inhibitors, clarified misconceptions around boxed warnings, and discussed the clinical relevance of recent label updates for abrocitinib.

Clarifying Allergy Controversies in Pediatric Atopic Dermatitis

At RAD 2025, pediatric dermatologist Lisa Swanson, MD, and allergist Anne Marie Singh, MD, led a dual session aimed at demystifying the connection between food allergy and atopic dermatitis.

Late-Breaking Data: Lebrikizumab Demonstrates Efficacy in Patients With Skin of Color With AD

At RAD 2025, Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color.

Late-Breaking Data: Real-World Registry Data Supports Upadacitinib Efficacy in Moderate to Severe AD, Regardless of Biologic History

At RAD 2025, Christopher Bunick, MD, PhD, presented 6-month data from the CorEvitas AD Registry, highlighting clinically meaningful skin clearance, itch reduction, and more in bio-naïve and bio-experienced adults treated with upadacitinib.

Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Catch up on coverage from the final day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

Chronic Itch Pathophysiology and Therapeutic Advances

At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.

Reviewing the Multifactorial Nature of Chronic Hand Eczema and Upcoming Delgocitinib

At the 2025 Revolutionizing Atopic Dermatitis Conference, JiaDe “Jeff” Yu, MD, MS, discussed the multifactorial nature of chronic hand eczema, highlighting its distinction from atopic dermatitis.

Late-Breaking Data: Real-World Data From Canada Shows Upadacitinib Is Effective in Patients With Moderate to Severe AD With Inadequate Response to Dupilumab

At RAD 2025, Vimal H. Prajapati, MD, shared phase 4 data from the CAN UpTIMISE study that shows switching to upadacitinib after inadequate response with dupilumab achieved rapid and significant improvements in skin clearance, itch, and QOL.

Recognizing Topical Steroid Withdrawal and Advancing Therapeutic Precision

At RAD 2025, Brad Glick, DO, MPH, reviewed the clinical signs of topical steroid withdrawal, the need for detailed patient histories to distinguish it from severe AD flares, and the role of targeted non-steroidal and systemic therapies.

Q&A: Dosing Flexibility Strategies for Oral and Biologic Therapeutics in AD With Raj Chovatiya, MD, PhD, MSCI

Raj Chovatiya, MD, PhD, MSCI, discussed his approach to personalizing treatment dosing plans with adult patients based on skin clearance and therapeutic type at RAD 2025.

RAD 2025 Poster Highlights Ruxolitinib Cream Safety in Combination AD Regimens

Recent research presented at the 2025 RAD Meeting explored the use of ruxolitinib cream in combination with systemic therapy.

Late-Breaking Data: Flexible Dosing of Abrocitinib for AD Shows Real-World Promise

Discover innovative insights from the JADE REAL study on flexible dosing of abrocitinib for managing moderate to severe atopic dermatitis.

Late-Breaking Data: Long-Term Safety and Efficacy of Nemolizumab for AD

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

OX40/OX40L Inhibitors Offer Upstream Signaling Pathways in Atopic Dermatitis

At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.

Late-Breaking Data: Positive Outcomes in Patients With Skin of Color With AD Using Dupilumab

At RAD 2025, the DISCOVER trial showed that dupilumab monotherapy significantly improved moderate to severe AD symptoms in this patient population.

Differentiating IL-31 and IL-13 Inhibition in Atopic Dermatitis

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

A Clinician’s Perspective of RAD 2025: Part 1

Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.

A Clinician’s Perspective of RAD 2025: Part 2

At RAD 2025, Maureen Offiah, MD, reflected on the sessions she felt were the most impactful as an attendee.

Q&A: Peter Lio, MD, on Safety in Pediatric AD Management and the Promise of Precision Medicine

Discover insights from Peter Lio, MD, on precision medicine in pediatric atopic dermatitis and the promising role of ruxolitinib at the RAD 2025 Conference.